Careteq Completes $5M Sale of Embedded Health Solutions, Focuses on HMR Referrals Platform

Completion of Embedded Health Solutions Sale

Careteq Limited (ASX:CTQ) has announced the completion of its divestment of Embedded Health Solutions (EHS), a fully owned subsidiary, to Nationwide Investments Holdings Pty Ltd. The transaction, initially agreed upon in February 2026, involved a business and asset sale agreement valued at $5 million, subject to customary purchase price adjustments related to working capital and employee entitlements, which totalled approximately $990,000.

The net proceeds from the sale were primarily used to settle a vendor loan of approximately $2.47 million, including outstanding interest, which Careteq had previously entered into in August 2024 when acquiring the remaining 45% minority interest in EHS. This repayment has relieved the company of a significant liability on its balance sheet.

Strategic Refocus on HMR Referrals Platform

Following the sale, Careteq intends to direct its resources towards expanding its HMR Referrals platform, which streamlines Home Medicines Reviews for the home care and disability sectors. The company views this as a core growth area and a strategic priority now that its financial position has been strengthened by the divestment.

This move aligns with Careteq’s broader strategy to concentrate on its health technology offerings, as previously outlined in its plans to divest Embedded Health Solutions for $5 million. The company continues to navigate challenges including an ongoing objection process with the Australian Taxation Office (ATO) concerning R&D tax claims, which remains unresolved.

ASX:Listing Rule Compliance and Potential Trading Suspension

The sale of Embedded Health Solutions constitutes a disposal of Careteq’s main undertaking, triggering obligations under ASX:Listing Rules 12.1 and 12.2. These rules require the company to demonstrate that its operations and financial condition remain sufficient to warrant continued quotation of its securities.

The ASX has granted Careteq a six-month period from the date of the disposal agreement (until 6 August 2026) to satisfy these requirements. Failure to demonstrate compliance to the ASX’s satisfaction by this deadline may result in suspension of trading in Careteq’s securities. Additionally, the company may be required to re-comply with Chapters 1 and 2 of the Listing Rules, potentially affecting its future transactions.

Outlook and Ongoing Considerations

Careteq’s Executive Chairman, Mark Simari, emphasised the company’s commitment to leveraging the improved balance sheet to support growth initiatives in its medication management platform. However, uncertainties remain regarding the outcome of the ATO objection process and the company’s ability to meet ASX compliance requirements within the stipulated timeframe.

Investors should monitor forthcoming updates on Careteq’s financial performance, regulatory status, and progress in expanding the HMR Referrals platform, which collectively will influence the company’s trajectory in the health technology sector.